Ethosuximide, Serum or Plasma
Also known as: Zarontin®
Use
Evaluate toxicity; monitor therapeutic levels
Special Instructions
State other drugs taken by patient. Avoid using gel-barrier tubes for specimen collection due to potential absorption of the drug by the gel, potentially affecting drug levels. Peak or trough levels can be monitored since blood levels are relatively constant.
Limitations
Ethosuximide blood levels may be affected by co-administration with drugs that induce or inhibit the P450 enzymatic system. Specimen collection using gel-barrier tubes may lead to decreased ethosuximide levels due to drug absorption by the gel. Proper storage and handling of the specimen are essential to ensure accurate results, as improper handling may compromise the test outcome.
Methodology
Immunoassay (IA)
Biomarkers
LOINC Codes
- 3616-0
- 3616-0
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.6 mL
Container
Red-top tube, lavender-top (EDTA) tube, or green-top (heparin) tube. Do not use a gel-barrier tube.
Collection Instructions
Transfer separated serum or plasma to a plastic transport tube. Oral: peak: two to four hours after dose; trough: immediately prior to next dose.
Storage Instructions
Room temperature
Causes for Rejection
Gel-barrier tube; hemolysis; lipemia; gross bacterial contamination
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |